Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 28, 2011

View Archived Issues

New vaccine shows promise in several models of infection

Phase III data support safety of dextromethorphan hydrobromide/quinidine sulfate in MS

Trial confirms earlier results with PET imaging agent florbetaben (18F)

Ampio Pharmaceuticals presents data from first-in-human Ampion trial

New TRPV4 channel antagonists disclosed

Adventrx and FDA agree on pivotal ANX-514 trial

Anthera Pharmaceuticals completes enrollment in PEARL-SC trial

MOC-carboetomidate induces hypnosis without adrenocortical suppression

Subcutaneous and intravenous secukinumab formulations evaluated in plaque psoriasis

Novel vasopressin V1A receptor antagonists designed by Roche

New Wnt signaling inhibitors discovered in Germany

TopoTarget patents new nicotinamide phosphoribosyltransferase inhibitors

Marina Biotech presents novel nucleic acid complexes

Intellect Neurosciences initiates development of new platform technology for proteinopathies

KemPharm to develop first-in-class oral hydromorphone prodrug

New Toll-like receptor 2 agonists prepared by IRM

Researchers at Abbott claim novel inhibitors of Bcl-2

Alexza Pharmaceuticals submits MAA for Adasuve

Marshall Edwards and Ausio Pharmaceuticals enter licensing agreement for AUS-131

Neuralstem completes phase Ia trial of NSI-189 in major depressive disorder

MHRA clears MediGene's clinical formulation study of RhuDex

Gilead files NDA for antiretroviral Quad regimen

European indication of Prevenar 13 extended

European Commission extends Alimta approval

FDA clears Ventana's companion algorithm for image analysis in HER2-positive breast cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...